Top of Page
Skip main navigation
COP Research Groups

Research

Dr. Omidian

Abuse-Resistant Medications, Reducing alcohol absorption into systemic circulation, Gastric retention oral drug delivery.
More ...

Dr. Rathinavelu

Cancer research conducted by Dr. Appu Rathinavelu at the college of Pharmacy Nova Southeastern University (NSU) is focused on developing new therapeutic methods for early detection of cancer and discovering new drugs that are useful for less toxic treatment of cancers. More ...

Dr. Latimer

DNA repair, stem cells, breast tissue engineering, breast cancer etiology, leukemia recurrence, genomic instability, mutation, precocial breast development, environmental causes of cancer, chemotherapy drugs that impact Nucleotide Excision Repair, somatic mutation in autism. More ...

Clark Research Group
Cardiovascular research conducted by Dr. Michelle A. Clark and her research team at Nova Southeastern University’s College of Pharmacy is focused on delineating the molecular pathways that are involved in blood pressure control. This research encompasses pharmacology and neuroscience, specifically determining the role of the renin-angiotensin system (RAS) in the control of hypertension and other types of cardiovascular diseases. More ...
Tassos Research Group
Molecular pharmacology, physiology and biology of G protein-coupled (heptahelical or seven transmembrane-spanning) receptors; Heart Failure; Cardiovascular Disease; Neurohormonal control of the Circulation; Adrenal Physiology and Pharmacology; Receptors for Adrenaline and Noradrenaline; Catecholamines; Receptors for Angiotensin II; Signal Transduction; Gene Therapy; Transgenic mice and rats; Aldosterone production regulation; Regulation of Adrenergic and Angiotensin Receptors; G protein-coupled receptor Kinases; Beta-Arrestins; Novel "Biased" G protein-coupled Receptor Ligands; Epicardial fat; Atrial Fibrillation; RGS proteins. More ...
Dr. Speth

Brain angiotensin system and its physiological actions, brain angiotensin receptors and binding sites, angiotensin metabolizing enzymes, radioligand binding assays, receptor autoradiography, radioiodination of ligands for receptor and enzyme characterization. More ...

Dr. Deth and team

The B.R.A.I.N. Institute (Brain Research and Integrated Nutrition) specifically focused on brain metabolism and the role of antioxidant and nutritional factors across the life span. More ...

Dr. Albensi

Benedict C. Albensi, Ph.D., BCMAS, CRQM is a Professor and Chair of the Department of Pharmaceutical Sciences. He is best known for his work with factors involved in ageing, cognition, and Alzheimer's disease (AD), such as nuclear factor kappa B (NF-kB), a mediator of inflammation but also a required molecule for memory.

He obtained his Ph.D. in Neuroscience from the University of Utah's Medical School in 1995. Subsequently, he was awarded a Postdoctoral Fellowship at Georgetown University in Washington, DC, working with Drs. Faden and Pekar, where he developed MRI methods for investigating head trauma and cognition. He then went on to work as a Postdoctoral Scholar with Dr. Mark Mattson, an internationally recognized leader and the most highly cited neuroscientist (for 20 years), at the Sanders-Brown Center on Aging - University of Kentucky. While in Dr. Mattson's lab he was the first to show NF-kB is required for hippocampal synaptic plasticity in mammals. Other appointments have included the Cleveland Clinic, NPS Pharmaceuticals, Pfizer, Case Western Reserve University, St. Boniface Hospital Research Ctr., and the University of Manitoba.

Over the last few years, his work has largely focused on mitochondrial dysfunction in AD.  Recently, the Albensi lab has shown very early deficits and sex-based differences in mitochondrial function before the appearance of plaques and tangles, the classic hallmarks of AD. He has been ranked in the top 1% worldwide by Expertscape.com for his number of publications from 2010-2020 in 7 areas including Alzheimer Disease (0.48%), neurocognitive disorders (0.76%), tauopathies (0.98%), dementia (0.85%), NF-kappa B (0.42%), memory (68%) & energy metabolism (0.68%).

Dr. Minond

Dmitriy Minond, Ph.D. is an Associate Professor in the Department of Pharmaceutical Sciences and Rumbaugh Goodwin Institute for Cancer Research. His research interests are drug and probe discovery for metalloproteases in cancer and other diseases. His main contribution to the field is a discovery of non-zinc-binding inhibitors for multiple zinc metalloproteases that are currently used for translational and pre-clinical studies for various therapeutic indications.

Dr. Minond received his undergraduate degree in Biology and Biochemistry from Odessa State University (Odessa, Ukraine) and doctorate in Chemistry and Biochemistry from Florida Atlantic University (Boca Raton, FL). Dr. Minond completed his post-doctoral studies at The Scripps Research Institute (2006-2010) after which became an Assistant Member at Torrey Pines Institute for Molecular Studies (2010-2015) and, consecutively, an Associate Professor at Harrison School of Pharmacy at Auburn University (2015-2017). Dr. Minond has joined NSU in 2017. Dr. Minond is a member of International Proteolysis Society and American Peptide Society. Dr. Minond authored more 50 scientific articles and book chapters. Dr. Minond is an inventor on patents for drug discovery in cancer, Alzheimer’s disease, and rheumatoid arthritis. He also serves as a reviewer for multiple scientific journals, NIH, and DOD grant review panels. Dr. Minond is a recipient of multiple grants, including Florida Biomedical Council and NIH R01 “HTS for selective inhibitors of meprin a and b” in collaboration with Scripps Florida.

Dr. Minond’s current research is focused on drug discovery for melanoma and rheumatoid arthritis.

Dr. Deth and team

Drug delivery and targeting, Multifunctional nanomedicines and nanobiomaterials, Theranostics, Bioengineering, Vaccines and immunotherapeutics, Diagnostic nanobiosystems.

More ...

Return to top of page